Undisclosed circRNA CD19/BCMA in vivo CAR-T / Therorna - LARVOL DELTA

In Vivo Generation of CD19/BCMA Dual-targeting CAR-T for Autoimmune Diseases (ACR Convergence 2026) - "The tLNP-delivered circRNA CD19/BCMA in vivo CAR-T achieves comprehensive B-cell depletion both in vitro and in vivo. By simultaneously targeting both pathogenic CD19+ B cells and the long-lived plasma cells, this off-the-shelf approach offers a highly accessible and potent therapeutic paradigm for the treatment of autoimmune diseases. Figure 1 Autologous B cell killing of dual-targeting circCARs in PBMCs derived from healthy donor or SLE patients."

CAR T-Cell Therapy • IO biomarker • Preclinical • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • CD8